FDA approves Pfizer Ibrance joint drug to treat male breast cancer patients
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Pfizer(http:// announcedthat the U.SFDA(http://approved the company's heavy-weight breast cancer treatment Ibrcicsito in conjunction with aromatase inhibitors or fuforvestts to treat HR, HER2-advanced or metastatic male breast cancer patientsthis approval is based on data used by male patients in the real world after theof electronic medical records anddrug(http:// on the marketThe 21st Century Healing Act, passed in 2016, laid the groundwork for the approval of real-world data-assisted drugs, and this time Ibrance's approval to expand the scope of indications was a success story in drug review using real-world dataThe FDA has also recently issued guidance documents that further clarify how it uses real data to help drug reviewsAbout IbranceIbrance is a CDK4/6 inhibitor that has been approved for use in postmenopausal women with aromatase inhibitors to treat HR plus HER2-late or metastatic breast cancerBased on data obtained from theinsurance database of theMedical (http:// of IQVIA, the Flatiron Health Breast Cancer Database and the Pfizer Global Security Database, the FDA found that Ibrance exhibited similar safety in both male and female patients
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
